Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth

Cancer Research

Volumn 72, Issue 17, 2012, Pages 4494-4503

  Surdez, Didier ^a,b   Benetkiewicz, Magdalena ^a,b   Perrin, Virginie ^a,b   Han, Zhi Yan ^a,b   Pierron, Gaëlle ^a   Ballet, Stelly ^a   Lamoureux, François ^c,d   Rëdini, Françoise ^c,d   Decouvelaere, Anne Valërie ^e   Daudigeos Dubus, Estelle ^f,g   Geoerger, Birgit ^f,g   De Pinieux, Gonzague ^h   Delattre, Olivier ^a,b   Tirode, Franck ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d INSERM   (France)

^e CENTRE LÉON BÉRARD   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g France   (France)

^h CHUde Tours   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; ENZASTAURIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EWING SARCOMA; EWSR1 FLI1 GENE; FEMALE; GENE EXPRESSION PROFILING; GENE FUSION; GENE OVEREXPRESSION; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; CALMODULIN-BINDING PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONES; HUMANS; MALE; MICE; MICE, NUDE; MICE, SCID; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN KINASE C; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA INTERFERENCE; RNA-BINDING PROTEINS; SARCOMA, EWING;

EID: 84865706519     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0371     Document Type: Article

References (47)

1. Aurias A, Rimbaut C, Buffe D, Zucker JM, Mazabraud A. Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. Cancer Genet Cytogenet 1984;12:21-5.
2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
3. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4.
4. Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 2008;7:250-6.
5. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-83.
6. Wai DH, Schaefer KL, Schramm A, Korsching E, Van Valen F, Ozaki T, et al. Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. Int J Oncol 2002;20:441-51.
7. Siligan C, Ban J, Bachmaier R, Spahn L, Kreppel M, Schaefer KL, et al. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene 2005;24:2512-24.
8. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 2006;4:851-9.
9. Mendiola M, Carrillo J, Garcia E, Lalli E, Hernandez T, de Alava E, et al. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer 2006;118:1381-9.
10. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006;9:405-16.
11. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 2009;28:4126-32.
12. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K, et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010;24:916-32.
13. Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR. Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma 2011;2011:402508.
14. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005;65:9226-35.
15. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, et al. A molecular function map of Ewing's sarcoma. PLoS One 2009;4:e5415.
16. Welford SM, Gregg J, Chen E, Garrison D, Sorensen PH, Denny CT, et al. Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization. Nucleic Acids Res 1998;26:3059-65.
17. Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdo-myosarcoma. J Clin Oncol 2010;28:2151-8.
18. R development core team. R: A language and environment for statistical computing. [homepage on the internet]. Vienna, Austria: R Foundation for Statistical Computing; 2006 [cited 2012 Jan 4]. Available from: http://www.R-project.org.
19. Culhane AC, Thioulouse J, Perriere G, Higgins DG. MADE4: an R package for multivariate analysis of gene expression data. Bioinformatics (Oxford, England) 2005;21:2789-90.
20. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005;33:e175.
21. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13.
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
23. Guillon N, Tirode F, Boeva V, Zynovyev A, Barillot E, Delattre O. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS One 2009;4:e4932.
24. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007;447:799-816.
25. Culhane AC, Perriere G, Considine EC, Cotter TG, Higgins DG. Between-group analysis of microarray data. Bioinformatics (Oxford, England) 2002;18:1600-8.
26. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009;218:86-94.
27. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70.
28. Foell JL, Hesse M, Volkmer I, Schmiedel BJ, Neumann I, Staege MS. Membrane-associated phospholipase A1 beta (LIPI) is an Ewing tumour-associated cancer/testis antigen. Pediatr Blood Cancer 2008;51:228-34.
29. Miyagawa Y, Okita H, Itagaki M, Toyoda M, Katagiri YU, Fujimoto J, et al. EWS/ETS regulates the expression of the Dickkopf family in Ewing family tumor cells. PloS One 2009;4:e4634.
30. Meynet O, Scotlandi K, Pradelli E, Manara MC, Colombo MP, Schmid-Antomarchi H, et al. Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness. Cancer Res 2010;70:3730-8.
31. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007;11:421-9.
32. Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 2010;464:792-6.
33. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9.
34. Tirado OM, MacCarthy CM, Fatima N, Villar J, Mateo-Lozano S, Notario V. Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer 2010;126:426-36.
35. Ikner A, Ashkenazi A. TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. J Biol Chem 2011;286:21546-54.
36. Abrams ST, Brown BR, Zuzel M, Slupsky JR. Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells. Blood 2010;115:4447-54.
37. Holzer G, Obermair A, Koschat M, Preyer O, Kotz R, Trieb K. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediatr Oncol 2001;36:601-4.
38. Shimokawa T, Seike M, Soeno C, Uesaka H, Miyanaga A, Mizutani H, et al. Enzastaurin has anti-tumour effects in lung cancers with over-expressed JAK pathway molecules. Br J Cancer 2012;106:867-75.
39. Serova M, Astorgues-Xerri L, Bieche I, Albert S, Vidaud M, Benhadji KA, et al. Epithelial-to-mesenchymal transition and oncogenic ras expression in resistance to the protein kinase Cb inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther 2010;9:1308-17.
40. Wei G-H, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 2010;29:2147-60.
41. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92.
42. Willey CD, Xiao D, Tu T, Kim KW, Moretti L, Niermann KJ, et al. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys 2010;77:1518-26.
43. Spalding AC, Watson R, Davis ME, Kim AC, Lawrence TS, Ben-Josef E. Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer. Clin Cancer Res 2007;13:6827-33.
44. Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai Y-T, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615. HCl). Blood 2007;109:1669-77.
45. Jian W, Yamashita H, Levitt JM, Lerner SP, Sonpavde G. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther 2009;8:1772-8.
46. Moreau A-S, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo Antitumor activity in Waldenström macroglobulinemia. Blood 2007;109:4964-72.
47. Meng XW, Heldebrant MP, Flatten KS, Loegering DA, Dai H, Schneider PA, et al. Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. J Biol Chem 2010;285:888-902.